December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

73.07 -1.16 (-1.56%)
Streaming Delayed Price Updated: 10:35 AM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. ↗
One analyst says the six-month study was too short and the benefits could appear over time. 
Via Investor's Business Daily
News headline image
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases. 
Via Benzinga
News headline image
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts ↗
 
Via Benzinga
News headline image
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood ↗
Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts ↗
 
Via Benzinga
News headline image
Where Ionis Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings) ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500 ↗
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
News headline image
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
News headline image
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
News headline image
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals ↗
 
Via Benzinga
News headline image
12 Analysts Have This To Say About Ionis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
News headline image
The Latest Analyst Ratings For Ionis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
From Biogen Inc.
Via GlobeNewswire
News headline image
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
News headline image
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong ↗
Biogen previously decided against opting into Ionis' Angelman program. 
Via Investor's Business Daily
News headline image
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Masters In Trading - Saturday, June 22 ↗
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. 
Via Talk Markets
News headline image
Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile ↗
Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year. 
Via Benzinga
News headline image
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder ↗
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS. 
Via Benzinga
News headline image
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another ↗
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes. 
Via Benzinga
News headline image
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
From Biogen Inc.
Via GlobeNewswire
News headline image
The 3 Most Undervalued Pharma Stocks to Buy in May 2024 ↗
Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.